Skip to content
10-Q

Quarterly Report

FINCH THERAPEUTICS GROUP, INC.

0000950170-24-057912

← back to feed
Filed
May 10, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 1.61M sh
Shares Diluted Q1 2024 · Mar 31, 2024 1.61M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 1.6M sh
Capex Q1 2024 · Mar 31, 2024 $0
Capex Q1 2024 · Mar 31, 2023 $14K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$4.36M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$13.38M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $20.76M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $25.12M
Stockholders Equity Q1 2024 · Mar 31, 2024 $19.04M
Stockholders Equity Q1 2024 · Dec 31, 2023 $22.89M
Stockholders Equity restated Q1 2024 · Mar 31, 2023 $34.54M
Stockholders Equity Q1 2024 · Dec 31, 2022 $95.71M
Current Liabilities Q1 2024 · Mar 31, 2024 $3.5M
Current Liabilities Q1 2024 · Dec 31, 2023 $4.08M
Total Liabilities Q1 2024 · Mar 31, 2024 $31.05M
Total Liabilities Q1 2024 · Dec 31, 2023 $32.49M
Current Assets Q1 2024 · Mar 31, 2024 $21.18M
Current Assets Q1 2024 · Dec 31, 2023 $25.85M
Total Assets Q1 2024 · Mar 31, 2024 $50.09M
Total Assets Q1 2024 · Dec 31, 2023 $55.37M
Eps Diluted Q1 2024 · Mar 31, 2024 −$2.41
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$39.19
Eps Basic Q1 2024 · Mar 31, 2024 −$2.41
Eps Basic restated Q1 2024 · Mar 31, 2023 −$39.19
Sga Expense Q1 2024 · Mar 31, 2024 $5.16M
Sga Expense Q1 2024 · Mar 31, 2023 $9.62M
Rd Expense Q1 2024 · Mar 31, 2024 $0
Rd Expense restated Q1 2024 · Mar 31, 2023 $7M
Net Income Q1 2024 · Mar 31, 2024 −$3.88M
Net Income restated Q1 2024 · Mar 31, 2023 −$62.35M
Operating Income Q1 2024 · Mar 31, 2024 −$5.2M
Operating Income restated Q1 2024 · Mar 31, 2023 −$65.78M
Revenue Q1 2024 · Mar 31, 2024 $0
Revenue Q1 2024 · Mar 31, 2023 $107K